Alan Ashworth, PhD, FRS

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    Ambagon
    Topic:
    SAB member
    Date added:
    09/14/2023
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    Earli
    Topic:
    SAB member
    Date added:
    09/14/2023
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    Phoenix Molecular Designs
    Topic:
    SAB member
    Date added:
    09/14/2023
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    Yingli
    Topic:
    SAB member
    Date added:
    09/14/2023
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    Hap10
    Topic:
    SAB member
    Date added:
    09/14/2023
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    Trial Library
    Topic:
    SAB member
    Date added:
    09/14/2023
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    Oric
    Topic:
    SAB member
    Date added:
    09/14/2023
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    ProLynx
    Topic:
    Advisor
    Date added:
    09/14/2023
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Novartis
    Topic:
    SAB member
    Date added:
    09/14/2023
    Date updated:
    09/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    GSK
    Topic:
    SAB member
    Date added:
    09/14/2023
    Date updated:
    09/14/2023

Pages

Return to 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes